Zacks Research Issues Positive Estimate for ResMed Earnings

ResMed Inc. (NYSE:RMD) – Research analysts at Zacks Research boosted their Q2 2025 earnings per share estimates for shares of ResMed in a research report issued to clients and investors on Thursday, December 5th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings per share of $2.25 for the quarter, up from their prior estimate of $2.24. The consensus estimate for ResMed’s current full-year earnings is $9.34 per share. Zacks Research also issued estimates for ResMed’s Q3 2025 earnings at $2.28 EPS, Q4 2025 earnings at $2.35 EPS, FY2025 earnings at $9.08 EPS, Q2 2026 earnings at $2.33 EPS, Q3 2026 earnings at $2.48 EPS, FY2026 earnings at $9.54 EPS, Q1 2027 earnings at $2.45 EPS and FY2027 earnings at $10.48 EPS.

A number of other equities analysts also recently issued reports on the company. StockNews.com raised ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Baird R W raised ResMed to a “strong-buy” rating in a research note on Tuesday, September 24th. Royal Bank of Canada increased their target price on ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a research note on Friday, October 25th. Needham & Company LLC reissued a “hold” rating on shares of ResMed in a research note on Friday, October 25th. Finally, Wolfe Research reissued an “underperform” rating and set a $180.00 target price on shares of ResMed in a research note on Wednesday, September 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $225.70.

ResMed Stock Performance

Shares of RMD stock opened at $245.22 on Monday. The company has a market cap of $36.00 billion, a price-to-earnings ratio of 32.48, a price-to-earnings-growth ratio of 1.75 and a beta of 0.68. The stock has a 50 day simple moving average of $242.31 and a 200-day simple moving average of $226.81. ResMed has a 12-month low of $162.18 and a 12-month high of $260.49. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.03 by $0.17. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The company had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.19 billion. During the same period last year, the firm earned $1.64 EPS. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis.

Institutional Investors Weigh In On ResMed

Hedge funds have recently made changes to their positions in the business. True Wealth Design LLC boosted its holdings in shares of ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 110 shares during the last quarter. Ashton Thomas Securities LLC acquired a new stake in shares of ResMed during the third quarter worth $34,000. OFI Invest Asset Management acquired a new position in ResMed in the second quarter valued at $32,000. Financial Connections Group Inc. acquired a new position in ResMed in the second quarter valued at $37,000. Finally, Blue Trust Inc. boosted its holdings in ResMed by 182.7% in the second quarter. Blue Trust Inc. now owns 212 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 137 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

Insider Buying and Selling at ResMed

In other news, insider Kaushik Ghoshal sold 5,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the sale, the insider now owns 21,788 shares in the company, valued at $5,502,777.28. This trade represents a 18.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Witte Jan De sold 796 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total value of $198,052.76. Following the sale, the director now owns 6,723 shares in the company, valued at $1,672,749.63. This trade represents a 10.59 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,725 shares of company stock worth $12,516,248. 0.71% of the stock is owned by insiders.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Thursday, November 7th. ResMed’s dividend payout ratio (DPR) is presently 28.08%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.